Relay Therapeutics' combo therapy cuts breast cancer progression in early study
Adds shares in paragraph 1
By Mariam Sunny and Sneha S K
Sept 9 (Reuters) -Relay Therapeutics RLAY.O said on Monday interim data from an early-stage study of its combination drug for breast cancer showed it meaningfully extended the time patients lived without the disease worsening, sending shares surging about 37% in early trading.
The main goal of the trial, which enrolled 118 heavily pre-treated patients with PI3K mutant, advanced breast cancer, was to test the safety and tolerability of the therapy.
The treatment, RLY-2608, in combination with AstraZeneca's AZN.L Faslodex, was generally well tolerated across all doses, the company said.
It helped 52 patients live for an average of 9.2 months without the disease worsening after treatment.
Astra's combination drug Truqap, approved for use in these patients, had helped improve the time patients with gene-altered tumors lived without their disease worsening by 7.3 months.
Two patients out of 64, who received a 600 milligram dose of the combination, discontinued the treatment due to related side effects, including itching and nausea, while one experienced severe hyperglycemia or high blood sugar.
Breast cancer is the second-most common cancer and the second-leading cause of cancer death among women in the U.S., according to American Cancer Society.
The therapy selectively targets a type of protein called PI3K, a mutation of which affects more than one in three people with breast cancer in the U.S., according to the company.
In 2019, Novartis' NOVN.S Piqray became the first approved PI3K inhibitor.
Piqray is "quite toxic and has a lot of side effects and it's very poorly tolerated by patients", Guggenheim analyst Michael Schmidt had said ahead of the interim data.
"At the end of the day, we look for ... better safety and better activity compared to, for example, drugs like Novartis' Piqray," Schmidt said.
If successful, Schmidt estimates U.S. peak sales of about $1.5 billion for the drug in second-line treatment of breast cancer.
Relay plans to start a late-stage trial for the combination next year, pending regulatory discussions.
Reporting by Mariam Sunny and Sneha S K in Bengaluru; Editing by Shilpi Majumdar
āĻ¸āĻŽā§āĻĒāĻ°ā§āĻāĻŋāĻ¤ āĻ ā§āĻ¯āĻžāĻ¸ā§āĻ
āĻ¸āĻ°ā§āĻŦāĻļā§āĻˇ āĻāĻŦāĻ°
āĻĻāĻžāĻŦāĻŋāĻ¤ā§āĻ¯āĻžāĻ: XM Group āĻāĻ° āĻ¸āĻ¤ā§āĻ¤ā§āĻŦāĻžāĻā§āĻ˛ā§ āĻļā§āĻ§ā§āĻŽāĻžāĻ¤ā§āĻ° āĻāĻžāĻ°ā§āĻ¯āĻāĻ° āĻ¸ā§āĻŦāĻž āĻĒā§āĻ°āĻĻāĻžāĻ¨ āĻāĻ°ā§ āĻāĻŦāĻ āĻāĻŽāĻžāĻĻā§āĻ° āĻ āĻ¨āĻ˛āĻžāĻāĻ¨ āĻā§āĻ°ā§āĻĄāĻŋāĻ āĻ¸ā§āĻŦāĻŋāĻ§āĻž āĻā§āĻ˛ā§ āĻāĻĒāĻā§āĻ āĻāĻ°āĻ¤ā§ āĻĻā§ā§, āĻ¸ā§āĻāĻ¸āĻžāĻĨā§ āĻāĻāĻāĻ¨ āĻŦā§āĻ¯āĻā§āĻ¤āĻŋāĻā§ āĻāĻ¯āĻŧā§āĻŦāĻ¸āĻžāĻāĻā§ āĻŦāĻž āĻāĻ° āĻŽāĻžāĻ§ā§āĻ¯āĻŽā§ āĻāĻĒāĻ˛āĻŦā§āĻ§ āĻŦāĻŋāĻˇāĻ¯āĻŧāĻŦāĻ¸ā§āĻ¤ā§ āĻĻā§āĻāĻ¤ā§ āĻāĻŦāĻ/āĻ āĻĨāĻŦāĻž āĻŦā§āĻ¯āĻŦāĻšāĻžāĻ° āĻāĻ°āĻžāĻ° āĻ āĻ¨ā§āĻŽāĻ¤āĻŋ āĻĻā§ā§ āĻ¤āĻŦā§ āĻāĻāĻŋ āĻā§āĻ¨ āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ āĻŦāĻž āĻĒā§āĻ°āĻ¸āĻžāĻ°āĻŋāĻ¤ āĻāĻ°āĻžāĻ° āĻāĻĻā§āĻĻā§āĻļā§āĻ¯ā§ āĻ¨āĻ¯āĻŧ āĻŦāĻž āĻāĻŽāĻ¨ āĻā§āĻ¨ āĻāĻžāĻ°āĻŖā§āĻ āĻ¨āĻ¯āĻŧāĨ¤ āĻāĻ āĻ§āĻ°āĻ¨ā§āĻ° āĻĒā§āĻ°āĻŦā§āĻļ āĻāĻŦāĻ āĻŦā§āĻ¯āĻŦāĻšāĻžāĻ° āĻ¸āĻŦāĻ¸āĻŽāĻ¯āĻŧ āĻāĻŋāĻā§ āĻŦāĻŋāĻˇā§ā§āĻ° āĻ¸āĻžāĻĨā§ āĻā§āĻŋāĻ¤: (i) āĻļāĻ°ā§āĻ¤āĻžāĻŦāĻ˛ā§; (ii) āĻā§āĻāĻāĻŋ āĻ¸āĻ¤āĻ°ā§āĻāĻ¤āĻž; āĻāĻŦāĻ (iii) āĻ¸āĻŽā§āĻĒā§āĻ°ā§āĻŖ āĻĻāĻžāĻŦāĻŋāĻ¤ā§āĻ¯āĻžāĻāĨ¤ āĻāĻ āĻ§āĻ°āĻ¨ā§āĻ° āĻŦāĻŋāĻˇāĻ¯āĻŧāĻŦāĻ¸ā§āĻ¤ā§ āĻ¤āĻžāĻ āĻ¸āĻžāĻ§āĻžāĻ°āĻŖ āĻ¤āĻĨā§āĻ¯ āĻšāĻŋāĻ¸ā§āĻŦā§ āĻāĻžāĻĄāĻŧāĻž āĻāĻ° āĻ āĻ¨ā§āĻ¯ āĻā§āĻ¨ āĻāĻĻā§āĻĻā§āĻļā§āĻ¯ā§ āĻĒā§āĻ°āĻĻāĻžāĻ¨ āĻāĻ°āĻž āĻšāĻ¯āĻŧ āĻ¨āĻžāĨ¤ āĻ āĻ¨ā§āĻā§āĻ°āĻš āĻāĻ°ā§ āĻŦāĻŋāĻļā§āĻˇāĻāĻžāĻŦā§ āĻ¸āĻā§āĻ¤āĻ¨ āĻĨāĻžāĻā§āĻ¨ āĻ¯ā§, āĻāĻŽāĻžāĻĻā§āĻ° āĻ āĻ¨āĻ˛āĻžāĻāĻ¨ āĻā§āĻ°ā§āĻĄāĻŋāĻ āĻ¸ā§āĻŦāĻŋāĻ§āĻžāĻ° āĻŦāĻŋāĻˇāĻ¯āĻŧāĻŦāĻ¸ā§āĻ¤ā§āĻā§ā§āĻ˛ā§ āĻāĻ°ā§āĻĨāĻŋāĻ āĻŦāĻžāĻāĻžāĻ°ā§ āĻā§āĻ¨ā§ āĻ˛ā§āĻ¨āĻĻā§āĻ¨ āĻāĻ°āĻžāĻ° āĻāĻ¨ā§āĻ¯ āĻ āĻ¨ā§āĻ°ā§āĻ§ āĻŦāĻž āĻĒā§āĻ°āĻ¸ā§āĻ¤āĻžāĻŦ āĻ¨āĻ¯āĻŧāĨ¤ āĻāĻžāĻ°āĻŖ āĻ¯ā§āĻā§āĻ¨ā§ āĻāĻ°ā§āĻĨāĻŋāĻ āĻŦāĻžāĻāĻžāĻ°ā§ āĻā§āĻ°ā§āĻĄāĻŋāĻ āĻāĻ°āĻ˛ā§ āĻāĻĒāĻ¨āĻžāĻ° āĻŽā§āĻ˛āĻ§āĻ¨ā§āĻ° āĻ¸āĻžāĻĨā§ āĻāĻāĻāĻŋ āĻāĻ˛ā§āĻ˛ā§āĻāĻ¯ā§āĻā§āĻ¯ āĻā§āĻāĻāĻŋ āĻāĻĄāĻŧāĻŋāĻ¤ āĻĨāĻžāĻāĻŦā§āĨ¤
āĻāĻŽāĻžāĻĻā§āĻ° āĻ āĻ¨āĻ˛āĻžāĻāĻ¨ āĻā§āĻ°ā§āĻĄāĻŋāĻ āĻ¸ā§āĻŦāĻŋāĻ§āĻžāĻ¯āĻŧ āĻĒā§āĻ°āĻāĻžāĻļāĻŋāĻ¤ āĻ¸āĻāĻ˛ āĻŦāĻŋāĻˇā§āĻŦāĻ¸ā§āĻ¤ā§ āĻļā§āĻ§ā§āĻŽāĻžāĻ¤ā§āĻ° āĻļāĻŋāĻā§āĻˇāĻžāĻāĻ¤/āĻ¤āĻĨā§āĻ¯āĻŽā§āĻ˛āĻ āĻāĻĻā§āĻĻā§āĻļā§āĻ¯ā§ āĻ¤ā§āĻ°āĻŋ āĻāĻ°āĻž āĻšāĻ¯āĻŧā§āĻ āĻāĻŦāĻ āĻāĻ¤ā§ āĻāĻ°ā§āĻĨāĻŋāĻ, āĻŦāĻŋāĻ¨āĻŋāĻ¯āĻŧā§āĻ āĻāĻ° āĻŦāĻž āĻā§āĻ°ā§āĻĄāĻŋāĻ āĻĒāĻ°āĻžāĻŽāĻ°ā§āĻļ āĻāĻŦāĻ āĻ¸ā§āĻĒāĻžāĻ°āĻŋāĻļ āĻ§āĻžāĻ°āĻŖ āĻāĻ°āĻž āĻāĻāĻŋāĻ¤ āĻ¨āĻ¯āĻŧ - āĻāĻŽāĻžāĻĻā§āĻ° āĻā§āĻ°ā§āĻĄāĻŋāĻ āĻŽā§āĻ˛ā§āĻ¯ā§āĻ° āĻāĻāĻāĻŋ āĻ°ā§āĻāĻ°ā§āĻĄ; āĻ āĻĨāĻŦāĻž āĻā§āĻ¨ā§ āĻāĻ°ā§āĻĨāĻŋāĻ āĻāĻĒāĻāĻ°āĻŖā§ āĻ˛ā§āĻ¨āĻĻā§āĻ¨ā§āĻ° āĻĒā§āĻ°āĻ¸ā§āĻ¤āĻžāĻŦ, āĻŦāĻž āĻ āĻ¨ā§āĻ°ā§āĻ§; āĻ āĻĨāĻŦāĻž āĻāĻĒāĻ¨āĻžāĻ° āĻāĻžāĻā§ āĻ āĻ¯āĻžāĻāĻŋāĻ¤ āĻāĻ°ā§āĻĨāĻŋāĻ āĻĒā§āĻ°āĻāĻžāĻ° āĻšāĻŋāĻ¸ā§āĻŦā§ āĻāĻāĻŋāĻā§ āĻ§āĻžāĻ°āĻŖ āĻāĻ°āĻž āĻāĻāĻŋāĻ¤ āĻ¨āĻ¯āĻŧāĨ¤
āĻā§āĻ¨ āĻ¤ā§āĻ¤ā§āĻ¯āĻŧ āĻĒāĻā§āĻˇā§āĻ° āĻŦāĻŋāĻˇā§āĻŦāĻ¸ā§āĻ¤ā§, āĻĒāĻžāĻļāĻžāĻĒāĻžāĻļāĻŋ XM āĻĻā§āĻŦāĻžāĻ°āĻž āĻĒā§āĻ°āĻ¸ā§āĻ¤ā§āĻ¤ āĻŦāĻŋāĻˇā§ āĻŦāĻ¸ā§āĻ¤ā§ āĻ¯ā§āĻŽāĻ¨ āĻŽāĻ¤āĻžāĻŽāĻ¤, āĻ¸āĻāĻŦāĻžāĻĻ, āĻāĻŦā§āĻˇāĻŖāĻž, āĻŦāĻŋāĻļā§āĻ˛ā§āĻˇāĻŖ, āĻĻāĻžāĻŽ, āĻ āĻ¨ā§āĻ¯āĻžāĻ¨ā§āĻ¯ āĻ¤āĻĨā§āĻ¯ āĻŦāĻž āĻāĻ āĻāĻ¯āĻŧā§āĻŦāĻ¸āĻžāĻāĻā§ āĻĨāĻžāĻāĻž āĻ¤ā§āĻ¤ā§āĻ¯āĻŧ āĻĒāĻā§āĻˇā§āĻ° āĻ¸āĻžāĻāĻā§āĻ° āĻ˛āĻŋāĻāĻ āĻā§āĻ˛ā§ "āĻ¯ā§āĻŽāĻ¨-āĻ°āĻ¯āĻŧā§āĻā§" āĻāĻŋāĻ¤ā§āĻ¤āĻŋāĻ¤ā§ āĻ¸āĻ°āĻŦāĻ°āĻžāĻš āĻāĻ°āĻž āĻšāĻ¯āĻŧ āĻ¸āĻžāĻ§āĻžāĻ°āĻŖ āĻŽāĻžāĻ°ā§āĻā§āĻā§āĻ° āĻāĻžāĻˇā§āĻ¯ āĻšāĻŋāĻ¸ā§āĻŦā§ āĻāĻŦāĻ āĻŦāĻŋāĻ¨āĻŋāĻ¯āĻŧā§āĻā§āĻ° āĻĒāĻ°āĻžāĻŽāĻ°ā§āĻļ āĻāĻ āĻ¨ āĻāĻ°āĻŦā§āĻ¨ āĻ¨āĻžāĨ¤ āĻ¯ā§āĻā§āĻ¨ā§ āĻŦāĻŋāĻˇāĻ¯āĻŧāĻŦāĻ¸ā§āĻ¤ā§āĻā§ āĻŦāĻŋāĻ¨āĻŋāĻ¯āĻŧā§āĻ āĻāĻŦā§āĻˇāĻŖāĻž āĻšāĻŋāĻ¸ā§āĻŦā§ āĻŦā§āĻāĻžāĻ¨ā§ āĻšāĻ˛ā§, āĻāĻĒāĻ¨āĻžāĻā§ āĻ āĻŦāĻļā§āĻ¯āĻ āĻŽāĻ¨ā§ āĻ°āĻžāĻāĻ¤ā§ āĻšāĻŦā§ āĻāĻŦāĻ āĻ¸ā§āĻŦā§āĻāĻžāĻ° āĻāĻ°āĻ¤ā§ āĻšāĻŦā§ āĻ¯ā§ āĻŦāĻŋāĻˇāĻ¯āĻŧāĻŦāĻ¸ā§āĻ¤ā§āĻāĻŋ āĻŦāĻŋāĻ¨āĻŋāĻ¯āĻŧā§āĻ āĻāĻŦā§āĻˇāĻŖāĻžāĻ° āĻ¸ā§āĻŦāĻžāĻ§ā§āĻ¨āĻ¤āĻžāĻ° āĻĒā§āĻ°āĻāĻžāĻ°ā§āĻ° āĻāĻ¨ā§āĻ¯ āĻĄāĻŋāĻāĻžāĻāĻ¨ āĻāĻ°āĻž āĻāĻāĻ¨āĻŋ āĻĒā§āĻ°āĻ¯āĻŧā§āĻāĻ¨ā§āĻ¯āĻŧāĻ¤āĻž āĻ āĻ¨ā§āĻ¸āĻžāĻ°ā§ āĻ¤ā§āĻ°āĻŋ āĻāĻ°āĻž āĻšāĻ¯āĻŧāĻ¨āĻŋ āĻāĻŦāĻ āĻāĻāĻŋ āĻŦāĻŋāĻŦā§āĻāĻ¨āĻž āĻāĻ°āĻž āĻšāĻŦā§ āĻ¨āĻž āĻĒā§āĻ°āĻžāĻ¸āĻā§āĻāĻŋāĻ āĻāĻāĻ¨ āĻ āĻĒā§āĻ°āĻŦāĻŋāĻ§āĻžāĻ¨ā§āĻ° āĻ āĻ§ā§āĻ¨ā§ āĻŦāĻŋāĻĒāĻŖāĻ¨ āĻ¯ā§āĻāĻžāĻ¯ā§āĻ āĻšāĻŋāĻ¸ā§āĻŦā§āĨ¤ āĻ āĻ¨ā§āĻā§āĻ°āĻš āĻāĻ°ā§ āĻ¨āĻŋāĻļā§āĻāĻŋāĻ¤ āĻāĻ°ā§āĻ¨ āĻ¯ā§ āĻāĻĒāĻ¨āĻŋ āĻ -āĻ¸ā§āĻŦāĻžāĻ§ā§āĻ¨ āĻŦāĻŋāĻ¨āĻŋāĻ¯āĻŧā§āĻ āĻ¸āĻāĻā§āĻ°āĻžāĻ¨ā§āĻ¤ āĻāĻŽāĻžāĻĻā§āĻ° āĻŦāĻŋāĻā§āĻāĻĒā§āĻ¤āĻŋ āĻĒāĻĄāĻŧā§āĻā§āĻ¨ āĻāĻŦāĻ āĻŦā§āĻā§āĻā§āĻ¨āĨ¤ āĻĒā§āĻ°ā§āĻŦā§āĻā§āĻ¤ āĻ¤āĻĨā§āĻ¯ āĻ¸āĻŽā§āĻĒāĻ°ā§āĻāĻŋāĻ¤ āĻāĻŦā§āĻˇāĻŖāĻž āĻāĻŦāĻ āĻā§āĻāĻāĻŋ āĻ¸āĻ¤āĻ°ā§āĻāĻ¤āĻž, āĻ¯āĻž āĻāĻāĻžāĻ¨ āĻĨā§āĻā§ āĻĒā§āĻ°āĻŦā§āĻļ āĻāĻ°āĻž āĻ¯ā§āĻ¤ā§ āĻĒāĻžāĻ°ā§āĨ¤